Replimune
REPL
19.07
-0.16
-0.83%
Replimune
US · REPL
#3130 by market cap
Listed 2018
19.07
-0.16
-0.83%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 6.7 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 107.69% -6.74pp
- Institutions
- 229 +1
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund48.14%
Hedge Fund46.08%
Public Company7.45%
VC/PE Fund3.12%
Private Company2.26%
Individual/Insider1.60%
Insurance Company0.39%
Government Pension Fund0.15%
Top holders as of 2026-08-09
Baker Bros. Advisors LP
11.65% · 11.05M sh
BlackRock
9.28% · 8.80M sh
RTW Investments, LP
7.82% · 7.41M sh
Ridgeback Capital Management LLC
7.71% · 7.31M sh
Montanova Capital, LLC
6.97% · 6.61M sh
State Street Global Advisors
4.40% · 4.17M sh
Boxer Capital Management, LLC
4.20% · 3.98M sh
Emerald Advisers, LLC
3.84% · 3.64M sh
Vanguard Capital Management, LLC
3.58% · 3.40M sh
Forbion Capital Partners B.V.
2.98% · 2.81M sh
The Goldman Sachs Group, Inc.
3.10% · 2.94M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 27 buys · 23 sells
| Name | Role | Stake |
|---|---|---|
| Baker Bros. Advisors LP | -- | 11.65% |
| Philip Astley-Sparke | Executive Chairperson | 1.35% |
| Sushil Patel | Chief Executive Officer | 0.08% |
| Konstantinos Xynos | Chief Medical Officer | 0.05% |
| Emily Hill | Chief Financial Officer | 0.04% |
| Christopher Sarchi | Former Chief Commercial Officer | 0.03% |
| Kapil Dhingra | Independent Director | 0.02% |
| Andrew Schwendenman | Chief Accounting Officer & Treasurer | 0.02% |
| Joseph Slattery | Independent Director | 0.00% |
| Julian Baker | -- | -- |
| Michael Goller | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-08 | Joseph Slattery | Independent Director | Open Market Disposition | -5,200 | $21.80 |
| 2026-11-02 | Paolo Pucci | Former Independent Director | Intent to Sell (Form 144) | -138,700 | $20.43 |
| 2026-11-01 | Kapil Dhingra | Independent Director | Derivative Exercise and Sale | -21,500 | $1.75–19.00 |
| 2026-11-01 | Kapil Dhingra | Independent Director | Derivative Exercise and Retained | +21,669 | $1.75 |
| 2026-10-29 | Veleka Peeples-Dyer | Former Independent Director | Intent to Sell (Form 144) | -10,000 | $16.72 |
| 2026-10-27 | Veleka Peeples-Dyer | Former Independent Director | Intent to Sell (Form 144) | -12,000 | $12.90 |
| 2026-08-19 | Philip Astley-Sparke | Executive Chairperson | Other Disposition | -50,000 | -- |
| 2026-08-16 | Emily Hill | Chief Financial Officer | Open Market Disposition | -9,256 | $14.28 |
| 2026-08-10 | Baker Bros. Advisors LP | -- | Open Market Derivative Acquisiti | +2,736,340 | $0.00 |
| 2026-08-09 | Emily Hill | Chief Financial Officer | Open Market Disposition | -11,448 | $12.97 |
| 2026-08-09 | Sushil Patel | Chief Executive Officer | Open Market Disposition | -39,341 | $12.97 |
| 2026-08-09 | Andrew Schwendenman | Chief Accounting Officer & Treasurer | Open Market Disposition | -7,632 | $12.97 |
| 2026-08-09 | Konstantinos Xynos | Chief Medical Officer | Open Market Disposition | -11,447 | $12.97 |
| 2026-05-31 | Christopher Sarchi | Former Chief Commercial Officer | Automatic Disposition | -12,000 | $9.24 |
| 2026-05-17 | Philip Astley-Sparke | Executive Chairperson | Open Market Disposition | -17,657 | $5.08 |
| 2026-05-17 | Emily Hill | Chief Financial Officer | Open Market Disposition | -7,812 | $5.08 |
| 2026-05-17 | Sushil Patel | Chief Executive Officer | Open Market Disposition | -37,324 | $5.08 |
| 2026-05-17 | Christopher Sarchi | Former Chief Commercial Officer | Open Market Disposition | -8,626 | $5.08 |
| 2026-05-17 | Andrew Schwendenman | Chief Accounting Officer & Treasurer | Open Market Disposition | -7,894 | $5.08 |
| 2026-05-17 | Konstantinos Xynos | Chief Medical Officer | Open Market Disposition | -14,023 | $5.08 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:01:05 · For reference only, not investment advice and not tailored to your situation.
Replimune discussion 0 comments